Data coverage, completeness and provenance for CLINUVEL PHARMACEUTICALS LIMITED in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T05:10:11. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 7.2200 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 7.3300 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 7.1800 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 7.2000 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 7.0100 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/CUV/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Website: https://www.clinuvel.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/CUV/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 31 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 31 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 31 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 31 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/CUV
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/CUV/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/CUV/metrics/summary
Dated press releases and announcements with source links.
GET /api/v1/companies/CUV/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/CUV
Free tier — instant API key. Built for AI agents.